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Abstract After a childhood episode of chicken pox, a Varicella-Zoster infection, the viral 
DNA reside in a dormant state in the dorsal root ganglia. The viruses get reactivated when the 
individual is immuno-compromised, in adulthood to cause characteristic lesions of Herpes zoster 
on the skin and the eyes. This case reports a 32 year old female who presented with neuralgia 
and clinical features of crusting skin ulcers involving the ophthalmic division of the trigeminal 
nerve, corneal dendritis and anterior uveitis with circumlimbal injection of the right eye. Visual 
acuity was OD: 6/60 and 0S:6/9. These clinical signs and symptoms were consistent with Herpes 
Zoster Ophthalmicus (HZO). Further medical laboratory tests showed positive for HIV and patient 
had a CD4+ count of 350 cells/ml of blood with a viral load of 100,000 copies/ml. Patient was 
subsequently treated of the Herpes zoster infection with Acyclovir (800 mg) prescribed five 
times daily for 7 days. While, at the HIV/AIDS project facility she was placed on Hyper Active 
Antiretroviral therapy (HAART): Stavudine (30 mg) bid for 2/12, Zidovudine (300 mg) bid for 
2/12 and Efavirenz (600mg) nocte for 2/12. There was complete resolution of the keratopathy, 
the visual acuity of OD improved to 6/12 by the 2nd month and the patient was without the 
experience of post herpetic neuralgia. At present (after 3 months) her CD4+ has increased to 
1000 cells/ml. HIV infection should always be considered in patients younger than 65 years with 
Herpes zoster ophthalmicus.
© 2011 Spanish General Council of Optometry. Published by Elsevier España, S.L. All rights reserved.
Virus herpes zóster oftalmológico como indicador de presencia de la enfermedad 
del VIH
Resumen Después de un episodio de varicela en la infancia, una infección del virus varicela-
zóster, el ADN vírico permanece en estado latente en los ganglios de la raíz dorsal. Los virus se 
reactivan cuando el sujeto está inmunodeprimido; en la edad adulta causa lesiones características 
del herpes zóster en la piel y en los ojos. Se reporta el caso de una mujer de 32 años con neuralgia 
y características clínicas de úlceras en la piel con costras implicando la división oftálmica del 
nervio trigémino, dendritis corneal y uveítis anterior con inyección circunlimbal del ojo derecho. 
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Introduction
Chicken pox (varicella) is a highly contagious skin disease 
primarily in children 2 to 7 years of age.1-3 The causative 
agent is the Varicella-Zoster virus, a member of the family 
Herpesviridae, which is acquired by droplet inhalation into 
the respiratory system.1 Following an incubation period 
from 10 to 23 days,4 small vesicles erupt on the face or 
upper trunk. These get filled with pus, get broken and 
become covered by crusting with an intense sensation of 
itching. Individuals who recover from chicken pox are 
subsequently immune to this disease; however they are not 
free of the virus as viral DNA resides in a dormant (latent) 
state in the dorsal root ganglia.5
Later in life when this primary infected person is 
immuno - comprom i sed ,  t he  v i r u s  may  become 
activated.3,6,7 The viruses migrate along afferent sensory 
nerves to the skin and eye where they replicate and cause 
the characteristic lesions.7,8 This reactivated form of 
chicken pox (Varicella) is termed Herpes Zoster. This report 
describes a HIVî2 positive patient who presented with 
Herpes zoster infection which affected the ophthalmic 
branch of the right trigeminal nerve.
Case report
A 32 year old female presented to the optometric facility of 
Central ophthalmic clinic in Eket, with complains of burning 
sensation and deep lancing pain on the surface of the right 
eye, upper lid, anterior scalp and forehead which followed 
soon after few days of fever, malaise and headache. 
Inspection showed skin lesions on the right half of the face, 
the frontal and the nasociliary i.e. the ophthalmic branch of 
the trigeminal nerve which have formed crusting ulcers.
The ocular signs were microdendritic ulcers on the right 
eye which were mostly peripheral with few central ones 
that abutted the visual axis. The microdendrites stained 
with Rose î Bengal. Another ocular sign on the OD was the 
presence of anterior uveitis with a circumlimbal injection. 
There was transient diplopia with restricted ocular 
movement when gaze was directed laterally and upward 
due to the involvement of the 3rd cranial nerve. Funduscopic 
examination revealed no retinal involvement. There was no 
abnormality detected (NAD) on the left eye. Visual acuity 
was OD: 6/60 and OS: 6/9. In addition the patient disclosed 
a previous childhood history of chickenpox during her 
primary school days, about 25 years ago. These signs and 
symptoms were consistent with Zoster.
Patient claimed to have enjoyed a general good health till 
this event, though agreed to have recently lost some 
weight. The patient was referred to the state owned 
Immanuel General Hospital, Eket for further medical 
laboratory tests. PCR test for Varicella î Zoster was positive. 
Genie II rapid HIV screening test was positive for HIV-2. The 
CD4+ count was 350 cells/ml blood and viral load was 
100,000 copies/ml.
In the optometric facility, patient was treated for Herpes 
Zoster Ophthalmicus (HZO) with oral Acyclovir (800 mg) 
prescribed 5 times daily for 7 days and topical prednisolone 
acetate (1%) 2 drops instilled four times daily for 7 days. 
The pupil of the right eye was kept dilated with Atropine 
(1%) of which 1drop was instilled three times daily for one 
week.
After one month, on appointment she returned to 
Immanuel General Hospital, to the Global HIV/AIDS 
initiative of Nigeria (GHAIN) project facility for her 
counseling. She was categorized “stage 2B” by the CDC 
clinical and immunological staging14 and placed on Hyper 
Active Antiretroviral Therapy (HAART): Stavudine (30 mg) 
bid × 2/12, Zidovudine (300 mg) bid × 2/12 and Efavirenz 
(600 mg) nocte × 2/12.
After 3 months on her HAART, her CD4+ count was 
increased to 1000 cells/ml and the viral load markedly 
reduced to less than 1,000 copies/ml. 
Her ophthalmic and Acyclovir medications prevented 
synaechia and the chronic form of cornea ulcer. There was a 
total resolution of the keratopathy. The visual acuity (VA) on 
the right eye improved to 6/12 by the second month; and 
presently the VA stands at 6/6+ on either eye. The patient 
also restored is a smooth ocular motility without the 
experience of diplopia. Patient has been also without 
the experience of a post-herpetic neuralgia. 
Discussion
A Herpesviridae is a double stranded DNA virus, with the 
outstanding property of establishing a lifelong persistent 
infection in their hosts by undergoing reactivation; with the 
La agudeza visual fue de OD 6/60 y OI 6/9. Estos signos y síntomas clínicos eran consistentes 
con manifestaciones del herpes zóster oftálmico (HZO). Los análisis clínicos posteriores dieron 
resultado de VIH positivo y la paciente presentó un recuento CD4+ de 350 células/ml en sangre 
con una carga vírica de 100.000 copias/ml. En consecuencia, la paciente recibió tratamiento con 
aciclovir (800 mg) 5 veces al día durante 7 días para la infección del herpes zóster. Asimismo, en 
el centro del proyecto HIV/AIDS la paciente recibió tratamiento antirretrovírico de gran actividad 
(HAART): estavudina (30 mg) 2 veces al día, zidovudina (300 mg) 2 veces al día y efavirenz (600 mg) 
nocte 2 veces al día. La queratopatía se resolvió completamente, la agudeza visual del OD mejoró 
hasta 6/12 en el 2.º mes y la paciente no presentó neuralgia posherpética. Actualmente (3 meses 
después), su CD4+ ha aumentado hasta 1000 células/ml. La posibilidad de infección por VIH siempre 
debe considerarse en pacientes menores de 65 años con herpes zóster oftálmico.
© 2011 Spanish General Council of Optometry. Publicado por Elsevier España, S.L. Todos los derechos 
reservados.
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reactivated infection being clinically quite different from 
the disease caused by primary infection.3
Varicella (Chickenpox) and Herpes zoster (Zoster) are 
different conditions caused by the same herpesviridae 
called VaricellaîZoster. While Varicella is common in 
children, Herpes Zoster mainly affects the elderlies.3,8,9
Throughout the world the incidence rate of herpes zoster 
every year ranges from 1.2 to 3.4 cases per 100 healthy 
individuals, increasing to 3.9-11.8 per 1,000 individuals 
among those older than 65 years.8
The current theory of etiology is that after an attack of 
chicken pox and its attendant viraemia, some virus spread 
along the sensory nerves from the skin lesions to be retained 
in the ganglia adjacent to the spinal cord (dorsal root 
ganglion) or the semilunar ganglion in the base of the 
skull.7,9 Later, under the influence of trigger factors 
particularly reduced immunity by such factors as 
psychological, physiological stress, age or AIDS, the virus 
reactivates and migrates along afferent sensory nerves to 
the skin and eye where it causes the characteristic facial 
lesions.2-7 This is directly the result of viral infection, 
antigen-antibody reactions, delayed cell mediated 
hypersensitivity reactions, denervation and ischaemia 
induced by vasculitis.
Approximately 15% of all cases of Herpes zoster affect the 
frontal, lacrimal and nasociliary branchesî that is the 
ophthalmic division of the trigeminal nerve.9 The condition 
is then referred to as Herpes Zoster ophthalmicus (HZO). 
The HIV positive population have a 15-25 times greater 
prevalence of zoster compared to the general population10
and the risk of developing HZO has been reported to be 
6.6 times higher than that of the general population.11
As occurs with other opportunistic infections in HIV, 
Herpes zoster can be more debilitating with greater skin 
and ocular involvements. HZO is usually described by a 
prodrome of fever, malaise and headache which typically 
herald the neuralgia component which precedes the 
cutaneous lesion of HZO. The neuralgia varies from itching, 
burning sensation to severe deep boring or lancing pain 
which is either persistent or intermittent. These may 
totally resolve within the  rst 4 weeks. Trigeminal neuralgia 
is caused by demyelination of trigeminal sensory fibres 
resulting from compression by an overlying blood vessel or 
in  ltrations.
The skin lesions of Herpes zoster are histopathologically 
identical to those of Varicella.3 The rashes may involve one 
or all the three branches of the ophthalmic distribution of 
the trigeminal nerve.9 Initially the lesion is maculopapular 
and then becomes pustular. The pustules subsequently burst 
to form crusting ulcers (  gure 1). The involvement of the 
nasociliary nerve (Hutchinson’s sign) which supplies the side 
of the nose correlates significantly with the subsequent 
development of ocular complications.12
Conjunctivitis is common and always associated with 
vesicles on the lid margins. This usually resolves within one 
week. If chronic, a mucus-secreting conjunctivitis may be 
accompanied with lipid-  lled granulomata under the tarsal. 
Episcleritis occurs in about 1/3 of cases at the onset of 
the rash but it is usually concealed by the overlying 
conjunctivitis; scleritis is much less common. When present, 
scleritis frequently becomes chronic and gives scleral 
atrophy, while a neglected sclerokeratitis yields a 
progressive scarring of the cornea.
Corneal complications occur in approximately 65% of 
cases with HZO. Punctate epithelial Keratitis develops in 
about 50% of patients within 2 days of the onset of the 
rash.10 The foci consist of swollen epithelial cells containing 
replicating virus. The lesions stain with Rose Bengal and are 
usually peripheral, multiple, raised, small and occasionally 
coated with mucous.
Microdendritic ulcers are also another mark of epithelial 
disease and appear within 4-6 days. HZO microdendrites are 
common and have no central ulceration or “terminal bulbs” 
like dendritic ulcers. The ulcers are usually peripheral, 
broader, more plaque like and more stellate shape than 
dendritic (  gure 2). 
Nummular keratitis is seen beneath the Bowman’s 
membrane in 33% of patients, 10 days after the onset of 
rashes. The lesion is characterized by multiple  ne granular 
deposits which are surrounded by a halo of stromal haze. 
Lesions may resolve without trace or become indolent with 
chronic cellular and lipid in  ltration that impair vision. 
Figure 1 Rashes distributed along the ophthalmic branches of 
the right Trigeminal of the patient.
Figure 2 Microdendrites on patient’s right cornea that stain 
with  ourescein.
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Disciform keratitis most at times follows nummular 
keratitis. It appears in 5% of cases 3 weeks after the onset
of rashes and usually central in location. If neglected there 
will be scarring, vascularization and deposition of lipid.
Mucous plaque keratitis develops in about 5% of cases at 
any time from two weeks of onset rashes. It is marked with 
a sudden onset of ciliary injection and mucous plaque
deposits on the surface of a diffusely swollen corneal 
epithelium. The white-grey plaque is adherent to the 
surface epithelium, with sharply demarcated margins and 
may be branched or linear. The plaques disappear after 
3 months leaving a faint diffused corneal haze.
The neurological complications are cranial nerve palsies 
particularly of the 3rd cranial pair. Recovery occurs 
spontaneously within six months. Optic neuritis occurs in 
about 1 in 400 cases. 
Many cases of acute retinal necrosis associated with 
Varicella-Zoster virus are without other clinical features of 
varicella or zoster infection elsewhere.9 Hence a laboratory 
diagnosis for VZV is recommended in acute retinal necrosis 
when there are no other ocular complication or skin lesions. 
A rise is specific antibody titer can be detected 
in the patient’s serum by tests l ike Complement 
Fixation, Neutralization Test (in cell culture), Indirect 
Immuno  uorescence and Enzyme immunoassay.
When vesicles are present, diagnoses in the laboratory 
can also be made by staining smears of scrapings or swabs of 
the base of vesicles and multinucleated giant cells are seen. 
These are absent in non-herpetic vesicles.3 Immuno  ourescein 
staining of smear can be used as well to detect intra cellular 
antigens.
In rapid diagnosis, in electron microscope examination, 
Varicella-zoster virus î speci  c antigens or viral DNA can be 
detected in vesicle  uid, in extracts of crust or in biopsy 
material.
The virus can also be isolated from vesicle fluid using 
cultures of human cell in 3-7 days. This is inoculated promptly 
since the virus is very labile in vesicle  uid. 
The presence of HZV in a young otherwise healthy patient 
should provide pause for the consideration of underlying 
HIV.
The laboratory diagnosis for HIV can be by viral isolation 
and culture, or by using assays for viral reserve transcriptase 
activity or viral antigens. However, diagnosis is best through 
the detection of speci  c anti HIV antibodies in the blood. 
These antibodies may be detected by GENIE or HIV AG 
(Abbott) rapid tests, the SUDS (Murex) 10 minute î assay, 
Enzyme-linked Immunoabsorbent Assay (ELISA), Indirect 
immunofluorescence, Immunoblot (Western Blot) and 
radioimmuno precipitation methods. 
HIV destroys the immune system for the fact that the 
virus-speci  c protein glycoprotein 120 envelope protein 
binds to the CD4 glycoprotein plasma membrane receptor 
on CD4+ T-cells, and HIV accumulates in lymphoid organs in 
large quantities even before symptoms appear. Thereafter 
the lymph nodes internal structure collapses due to viral 
replication. This leads to a decline in the number of 
lymphocytes within the lymph nodes and results in a 
selective depletion of the CD4+ T-cell subset.13 When this 
CD4+ population declines, it leaves the infected person 
open to opportunistic infections.1,13 In 1993 the CDC 
de  ned AIDS to include all HIV infected persons who have 
fewer than 200 CD4+ cells per ml or a CD4+ cell percentage 
of total lymphocytes of less than 14. Healthy individuals 
have about 1000 of such cells in every ml of blood. In HIV 
infected individuals, the number declines by an average of 
about 40 to 80 cells per ml each year.13 When the CD4+ cell 
count falls to between 400 and 200 per ml the first 
opportunistic infections and disease processes usually 
appear.14
Herpers zoster may occur at any stage of HIV infection 
and be its first clinical presentation.15,16 The risk of 
developing herpes zoster is not associated with duration of 
HIV infection or rapid progress to AIDS, nevertheless patients 
with CD4+ counts between 50 and 200 cells/ml seem to be at 
the highest risk of a herpes zoster event.17
At present there is no complete cure for AIDS. Primary 
treatment is directed at reducing the viral load and 
increasing the CD4+ count as well as at treating the 
opportunistic infections.
Treatment of Herpes Zoster Ophthalmicus is with oral 
antiviral drugs, mydriatics and topical corticosteroids. Early 
treatment with Acyclovir 800 mg 5 times a day; Famicidovir 
500 mg or Valacylovir 1 gram t.i.d for 7 days reduce ocular 
complications. Patients with keratitis or uvetis require 
topical corticosteroids e.g. prednisolone acetate 1% instilled 
q.i.d initially, lengthening the interval as symptoms 
improve. The pupil should be dilated with Atropine 1% or 
scopolamine 0.25% 1 drop t.i.d., intraocular pressure must 
be monitored and treated if it rises significantly above 
normal values. For the symptoms, the use of a brief course 
of high doses of corticosteroids to prevent post herpetic 
neuralgia in patients more than 60 years who are in good 
general health remains controversial.12
In our optometric facility this case was treated for Herpes 
Zoster Ophthalmicus (HZO) with oral Acyclovir (800 mg) 
prescribed 5 times daily for 7 days and topical prednisolone 
acetate (1%) 2 drops instilled four times daily for 7 days. 
The pupil of the right eye was kept dilated with atropine 
(1%) of which 1 drop was instilled three times daily for one 
week. There was a total resolution of the keratopathy. The 
visual acuity (VA) on the right eye improved to 6/12 by the 
second month; and presently the VA stands at 6/6+ on either 
eye. The patient also restored a smooth ocular motility 
without the experience of diplopia. Patient has been 
also without the experience of a post-herpetic neuralgia. A 
post-herpetic neuralgia affects about 7% of patient and may 
lead to depression.9
The antivirals currently approved for use in HIV disease to 
increase the CD4+ count and reduce the viral load are of 
three types.18
1. Nucleoside reverse Transcriptase inhibitors (NRTIS). 
Examples are Zidovudine (AZT), Stavudine (d4t), 
Lamivudine (3TC), Didanosine (ddi), Abacavir (ABC), 
Zalcitabine (ddc) and Emtricitabine.
2. The Nonnucleoside Inhibitors of Revene Trans criptase 
(NNRTIS). Examples are Neviropine (NVP), Efavirenz 
(EFV) and Delaviridine (DLV).
3. The protease inhibitors (PI) work by blocking the activity 
of the HIV protease and thus interfere with vision 
assembly. Examples are Saquinavir (SQV) indinavir (IDV), 
Ritonavir (RTV), Nel  navir (NFV), Amprenavir (APV) and 
Lopinavir (LPV).
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Therapy with combinations of antiretroviral, such as the 
combination of AZI, ZTC and RTV, at high dosages to prevent 
the development of resistance is referred to as Highly Active 
Antiretroviral Therapy (HAART). It suppress viral replication 
to below limits of detection in plasma and decrease viral 
loads in lymphoid tissue, allowing the recovery of immune 
response to opportunistic pathogens.19,20
The patient was placed on Hyper Active Antiretroviral 
Therapy (HAART): Stavudine (30 mg) bid × 2/12, Zidovudine 
(300 mg) bid × 2/12 and Efavirenz (600 mg) nocte × 2/12. 
After 3 months on her HAART the viral load was markedly 
reduced to less than 1,000 copies/ml and her CD4+ count 
increased to 1000 cell/ml.
If HIV treatment is started early enough the immune 
system (as monitored by the increased CD4+ count) will be 
recovered after HIV levels have fallen.21 This prevents the 
development of opportunistic infections. Hence the need 
for early detection of HIV. Recognition of potential 
opportunistic infections in selected patients will help 
achieve the goal of early detection of HIV.
HIV infection should always be considered in patients 
younger than 65 years with herpes zoster ophthalmicus.15,22
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